Mounjaro and HRT: Safety and Interactions

Mounjaro and HRT are increasingly being used together by women navigating perimenopause and menopause, two life stages where weight management and hormonal health often intersect. Mounjaro (tirzepatide) is MHRA-authorised for chronic weight management and type 2 diabetes, while HRT addresses menopausal symptoms such as hot flushes, mood changes and sleep disturbance. As hormonal shifts during menopause can contribute to weight gain and metabolic changes, some women meet the criteria for both treatments simultaneously. This article explains what is currently known about using these medicines together, including safety considerations, potential interactions and what UK guidance advises.

Why are people taking Mounjaro and HRT together?

Women take Mounjaro and HRT together because menopausal hormonal changes promote central weight gain, meaning many women simultaneously meet eligibility criteria for both a weight-management medicine and HRT for symptom relief.

Many women are taking Mounjaro (tirzepatide) and hormone replacement therapy (HRT) at the same time because both medicines address conditions that frequently coincide during perimenopause and menopause. Mounjaro is authorised by the MHRA both for the management of type 2 diabetes in adults and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. HRT is prescribed to relieve menopausal symptoms such as hot flushes, mood changes, sleep disturbance and vaginal dryness, as described in NICE guideline NG23 (Menopause: diagnosis and management).^[4][5]

Hormonal changes during perimenopause are associated with shifts in body composition, including increased central adiposity and a tendency towards weight gain, which can make achieving or maintaining a healthy weight more difficult.^[23][24] Women who are already using HRT for symptom control may therefore also meet the eligibility criteria for a weight-management medicine such as Mounjaro.

Some women find that menopausal weight gain contributes to conditions such as type 2 diabetes, hypertension or dyslipidaemia, which are precisely the comorbidities that may make them eligible for tirzepatide under its licensed indications. The result is that some women are, under medical supervision, using both treatments simultaneously.

Importantly, HRT is not a form of contraception. Women who are perimenopausal and for whom pregnancy is possible should use appropriate contraception alongside HRT. This should be discussed with a GP or specialist.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where Mounjaro is one option a prescriber may consider after a consultation if it is clinically appropriate.

Is it safe to use Mounjaro alongside HRT?

There is no contraindication to combining Mounjaro and HRT, but tirzepatide's effect on gastric emptying may reduce absorption of oral HRT; transdermal or vaginal preparations are unaffected and may be preferable.

The Mounjaro UK Summary of Product Characteristics (SmPC) does not list a contraindication to concurrent HRT use. The only contraindication in the UK SmPC (section 4.3) is hypersensitivity to tirzepatide or any excipient. However, the SmPC (section 4.5) notes that tirzepatide slows gastric emptying, which is part of its mechanism of action as a dual GIP and GLP-1 receptor agonist, and that this may reduce the rate and extent of absorption of orally administered medicines. The SmPC specifically notes reduced exposure to oral hormonal contraceptives following tirzepatide initiation and after each dose increase, and advises that women using oral hormonal contraceptives switch to a non-oral method or add a barrier method for four weeks after starting tirzepatide and for four weeks after each dose escalation.^[2][8] Although this guidance relates to oral contraceptives, the same absorption mechanism is relevant to oral oestrogen and oral progesterone preparations used in HRT, and the clinical significance for oral HRT has not been formally quantified in published studies. It is therefore not accurate to say there is no pharmacokinetic consideration between tirzepatide and oral HRT; rather, no dedicated interaction study has been conducted, and a plausible effect on oral HRT absorption exists.

Transdermal HRT (patches, gels or sprays) and vaginal preparations bypass the gastrointestinal tract entirely and are not subject to this absorption concern. Women using oral HRT who are starting Mounjaro should raise this with their GP or specialist, who may wish to review the formulation of HRT being used. Switching to a transdermal or vaginal route may be appropriate in some cases, and this should be a shared decision informed by NICE NG23 and individual clinical circumstances.

The Mounjaro SmPC (section 4.6) states that tirzepatide is not recommended during pregnancy or breastfeeding. Women who are perimenopausal and could still conceive should use effective contraception, as HRT alone does not provide contraceptive protection.

Women should always inform all their prescribers and their pharmacist that they are taking both medicines. Any suspected adverse effects from either medicine should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Does HRT affect how well Mounjaro works for weight loss?

No evidence suggests HRT reduces Mounjaro's efficacy; HRT may even partially support weight-management goals by mitigating some metabolic effects of declining oestrogen during menopause.

No evidence has been identified to suggest that HRT directly reduces the efficacy of Mounjaro for weight management. Tirzepatide works by activating GIP and GLP-1 receptors, reducing appetite, slowing gastric emptying and improving insulin sensitivity. These mechanisms are not known to be antagonised by the oestrogen or progesterone components of standard HRT.

In the clinical trials supporting Mounjaro's weight-management licence (the SURMOUNT programme, summarised in the EMA European Public Assessment Report), participants achieved clinically meaningful reductions in body weight.^[7][12] These trials did not specifically stratify results by menopausal status or concurrent HRT use, so it is not possible to state with precision how much weight loss a woman on HRT should expect compared with a woman who is not. Individual responses to tirzepatide vary considerably depending on factors including baseline weight, dietary habits, physical activity, adherence and underlying metabolic health.

Some evidence, including data referenced in NICE NG23, suggests that oestrogen replacement may have a modest effect on body composition during menopause, though the magnitude and clinical relevance of this effect vary between individuals and studies.^[19][20] The hormonal environment of menopause, characterised by declining oestrogen, can make weight loss more challenging through effects on metabolism, muscle mass and fat distribution. HRT may partially mitigate some of these hormonal effects, which could in theory support rather than hinder weight-management goals alongside Mounjaro.

Women should set realistic expectations in discussion with their prescriber and should not discontinue either medicine without medical advice. Regular review appointments are important to assess progress and adjust treatment as needed.

What side effects should you watch for when combining these medicines?

Monitor for tirzepatide side effects such as nausea and vomiting, and HRT effects such as breast tenderness; serious symptoms including severe abdominal pain or sudden leg swelling require urgent medical attention.

When taking Mounjaro and HRT together, the side effects to monitor are primarily those associated with each medicine individually, as no unique interaction-specific adverse effects have been formally identified in UK clinical guidance.

The most commonly reported side effects of tirzepatide, as listed in the Mounjaro UK SmPC (section 4.8), include nausea, vomiting, diarrhoea, constipation, reduced appetite and injection-site reactions. These are most pronounced during dose escalation and typically improve over time.

HRT carries its own side effect profile depending on the formulation and hormones used. Common effects include breast tenderness, bloating, headaches and mood changes, particularly in the early weeks of use. Some symptoms, such as nausea or bloating, could originate from either medicine, which can make attribution difficult. Keeping a symptom diary and discussing it with a GP or specialist can help clarify the source.

More serious considerations include:

• Pancreatitis: The Mounjaro UK SmPC notes that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[2][9] Persistent, severe abdominal pain radiating to the back should prompt urgent medical assessment. Contact NHS 111 for urgent advice or attend A&E if symptoms are severe.

• Gallbladder disease: Cholelithiasis and cholecystitis are listed in the Mounjaro SmPC (section 4.8). Rapid weight loss of any cause can increase the risk of gallstones. Symptoms such as right upper abdominal pain, particularly after eating, should be discussed with a GP.

• Thyroid symptoms: The Mounjaro UK SmPC (section 4.4) advises that patients are counselled on symptoms such as a neck lump, hoarseness or difficulty swallowing, and to contact their doctor if these occur. The human relevance of thyroid C-cell findings observed in animal studies is uncertain.

• Hypoglycaemia: Women taking Mounjaro alongside insulin or a sulfonylurea for type 2 diabetes have an increased risk of hypoglycaemia. This should be discussed with a prescriber, who may adjust doses of these medicines accordingly.

• HRT-related risks: HRT, depending on the regimen and route, is associated with a small increased risk of venous thromboembolism (VTE) and stroke, particularly with oral preparations.^[15][16] Red-flag symptoms requiring urgent medical attention include sudden unilateral leg swelling or pain, sudden chest pain, or breathlessness. Unexpected vaginal bleeding in a woman on HRT should always be discussed promptly with a GP. Women on HRT should continue routine breast awareness and attend NHS breast screening as invited. Full information on HRT risks is available from NICE NG23 and the NHS HRT pages.

If you experience any new or worsening symptoms while taking either medicine, contact your GP or call NHS 111.

What do UK doctors and NICE guidance say about this combination?

No specific NICE or UK professional body guidance exists for this combination; clinicians follow individual medicine licences, with NICE NG23 covering HRT and a separate NICE Technology Appraisal covering tirzepatide.

Neither NICE nor any UK professional body has issued specific guidance on the concurrent use of Mounjaro and HRT, reflecting the fact that this combination has not been the subject of a dedicated technology appraisal or clinical guideline. NICE has appraised tirzepatide for chronic weight management (see the relevant NICE Technology Appraisal, which sets out eligibility criteria for NHS use), and separate NICE guidance addresses the management of menopause, including the use of HRT (NICE NG23, updated 2024). The two sets of guidance exist independently and do not address the combination directly.

In practice, UK clinicians are guided by the individual licences of each medicine, the clinical needs of the patient and their professional judgement. The MHRA has authorised Mounjaro for both type 2 diabetes management and chronic weight management in adults. HRT prescribing is supported by NICE NG23, which supports its use for symptom relief and acknowledges its role in reducing the risk of osteoporosis.^[4][5] There is no regulatory or clinical guidance that prohibits the two being used together.

Women who are considering or already using both medicines are advised to:

• Inform all prescribers of every medicine they are taking, including HRT formulation and route of administration.

• Discuss HRT formulation with their GP if they are using oral preparations, given tirzepatide's effect on gastric emptying and potential impact on oral drug absorption.

• Attend regular reviews with their GP or specialist to monitor weight, metabolic parameters and symptom control.

• Contact their GP if they have concerns about either medicine or notice new or worsening symptoms.

Local NHS commissioning of Mounjaro for weight management is determined by individual Integrated Care Boards (ICBs), and access may vary by region. Eligibility also depends on local pathway criteria and service capacity. Women should speak to their GP for guidance on what is available in their area.

Scientific References

1. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
2. Mounjaro KwikPen 10 mg solution for injection in pre-filled pen – Summary of Product Characteristics.
3. Tirzepatide for managing overweight and obesity (TA1026).
4. Menopause: identification and management (NG23).
5. Menopause: identification and management – Recommendations chapter (NG23).
6. Mounjaro (tirzepatide) – EPAR Product Information.
7. Mounjaro – EPAR Assessment Report (Variation: chronic weight management).
8. Women on 'skinny jabs' must use effective contraception – MHRA guidance.
9. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
10. Tirzepatide – BNF drug monograph.
11. Use of incretin-based therapies in women using hormone replacement therapy.
12. Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-4).
13. Results from the SURMOUNT-1 study (health-related quality of life outcomes).
14. Achieving the triple endpoint of body weight reduction thresholds … with tirzepatide: A post hoc analysis from the SURMOUNT trials.
15. Long-term benefits and risks of hormone replacement therapy – NICE consultation.
16. NG23 Recommendations for research: venous thromboembolism and HRT.
17. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis.
18. NG23 Early menopause evidence review (including osteoporosis and HRT).
19. Understanding weight gain at menopause.
20. Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone.
21. Role of ovarian hormones in the regulation of protein metabolism in women: effects of menopausal status and hormone replacement therapy.
22. The effect of hormone replacement therapy and/or exercise on skeletal muscle attenuation in postmenopausal women.
23. Menopausal obesity – myth or fact?.
24. Body mass changes at menopause: impact of therapeutic strategies.
25. Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy.

Frequently Asked Questions